Winnergy Medical Public Company Limited Stocks

THB 0.9Last Updated 27.04.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

THB 11.36M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
THB 0.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Winnergy Medical Public Company Limited engages in the distribution of medical and diagnostic equipment in Thailand. The company sells women healthcare products, including down's syndrome and genetic screening test, pregnancy monitoring, and cervical dilators; equipment for testing blood quality to donate blood; blood infection testing products; and stem cell and contamination analysis products. It also sells mosquito trappers for outdoor and indoor use; and offers COVID-19 diagnostic lab services. The company was formerly known as Winnergy Medical Co., Ltd. and changed its name to Winnergy Medical Public Company Limited in September 2020. Winnergy Medical Public Company Limited was founded in 2004 and is headquartered in Bangkok, Thailand.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks